Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
FDA Expands Approval of Fulvestrant for Advanced Breast CancerFDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy.
-
Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra KaplanNCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.
-
Long-Term Nerve Damage Possible after Chemotherapy for Breast CancerMany women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.
-
FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic LeukemiaFDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.
-
FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian CancerFDA has granted regular approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy.
-
Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of DeathIn a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.
-
CAR T-Cell Therapy Approved for Some Children and Young Adults with LeukemiaFDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL).
-
Crizotinib Shows Promise for Childhood CancersIn a small clinical trial, the drug crizotinib shrank tumors in children with cancers that have alterations in the ALK gene.
-
New on NCI’s Websites for September 2017NCI periodically provides updates on new websites and other online content of interest to the cancer community.
-
Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI SupportResearchers recognized the potential of endoxifen as a treatment for breast cancer and, with NCI support, developed the compound into a drug now being tested in clinical trials.
-
Modified Stem Cells Deliver Chemotherapy to Metastatic TumorsResearchers have used modified stem cells to deliver a cancer drug selectively to metastatic breast cancer tumors in mice. The stem cells target metastatic tumors by homing in on the stiff environment that typically surrounds them.
-
Two New Therapies Approved for Acute Myeloid LeukemiaFDA has approved two new treatments for some adult patients with acute myeloid leukemia (AML): enasidenib (Idhifa®), which targets the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos®), a two-drug chemotherapy combination encapsulated in liposomes.
-
Heart Attack, Stroke Risk May Be Elevated Following Cancer DiagnosisA diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months after beginning treatment, a new study suggests. Within 6 months of a diagnosis, the risk of either event was more than twice that seen in people without cancer.
-
Neratinib Approved by FDA for HER2-Positive Breast CancerFDA has approved neratinib for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab.
-
NCI Program Supports Small Businesses to Advance Cancer Research Innovation – A Q&A with Michael WeingartenNCI’s Small Business Innovation Research Program recently issued contract solicitations to spur the development of new cancer-related therapies and technologies, including seven opportunities specific to the Cancer Moonshot.
-
FDA Approves Nivolumab for Some Metastatic Colorectal CancersFDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with metastatic colorectal cancer whose tumors have alterations that affect DNA repair.
-
Study Uncovers Previously Unrecognized Effect of ChemotherapyA new study conducted primarily in mice suggests that chemotherapy given before surgery for breast cancer can cause changes in cells in and around the tumor that are tied to an increased risk of the cancer spreading to other areas of the body.
-
Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host DiseaseA drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.
-
Dual-Biomarker Blood Test Shows Promise for Pancreatic Cancer Early DetectionA new blood test that measures levels of two specific proteins may be able to accurately detect pancreatic cancer at its earliest stages, when it is most likely to respond to treatment, findings from a new study suggest.
-
“First in Human” Documentary Highlights NCI Immunotherapy ResearchThe Discovery Channel special, First in Human, will feature some of the groundbreaking work on cancer immunotherapy being done at the NIH Clinical Center, including CAR T-cell therapy and TIL therapy.